Elevated hepatic fatty acid oxidation, high plasma fibroblast growth factor 21, and fasting bile acids in nonalcoholic steatohepatitis

European Journal of Gastroenterology and Hepatology

Volumn 23, Issue 5, 2011, Pages 382-388

  Dasarathy, Srinivasan ^a   Yang, Yu ^a   McCullough, Arthur J ^a   Marczewski, Susan ^a   Bennett, Carole ^a   Kalhan, Satish C ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Bile acids; fatty acid oxidation; fibroblast growth factor 21; nonalcoholic steatohepatitis

Indexed keywords

3 HYDROXYBUTYRIC ACID; 8 HYDROXYDEOXYGUANOSINE; ALANINE AMINOTRANSFERASE; BILE ACID; CERAMIDE; FATTY ACID; FIBROBLAST GROWTH FACTOR 21; GLUCOSE; GLYCOCHOLIC ACID; INSULIN; INTRALIPID; LEPTIN; TAUROCHENODEOXYCHOLIC ACID; TAUROCHOLIC ACID;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BILE ACID BLOOD LEVEL; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; FATTY ACID BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; HORMONE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; LIPID BLOOD LEVEL; LIPID OXIDATION; MALE; NONALCOHOLIC FATTY LIVER; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

3-HYDROXYBUTYRIC ACID; ADULT; ALANINE TRANSAMINASE; BILE ACIDS AND SALTS; BLOOD GLUCOSE; BODY MASS INDEX; CERAMIDES; DEOXYGUANOSINE; EMULSIONS; FATTY ACIDS; FATTY LIVER; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; INSULIN; LEPTIN; MALE; MIDDLE AGED; OXIDATIVE STRESS; PHOSPHOLIPIDS; SOYBEAN OIL;

EID: 79955052166     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e328345c8c7     Document Type: Article

References (57)

1. Kotronen A, Seppala-Lindroos A, Vehkavaara S, Bergholm R, Frayn KN, Fielding BA, et al. Liver fat and lipid oxidation in humans. Liver Int 2009; 29:1439-1446.
2. Miele L, Grieco A, Armuzzi A, Candelli M, Forgione A, Gasbarrini A, et al. Hepatic mitochondrial beta-oxidation in patients with nonalcoholic steatohepatitis assessed by 13C-octanoate breath test. Am J Gastroenterol 2003; 98:2335-2336. (Pubitemid 37305387)
3. Nakamuta M, Kohjima M, Higuchi N, Kato M, Kotoh K, Yoshimoto T, et al. The significance of differences in fatty acid metabolism between obese and nonobese patients with non-alcoholic fatty liver disease. Int J Mol Med 2008; 22:663-667.
4. Perez-Carreras M, Del HP, Martin MA, Rubio JC, Martin A, Castellano G, et al. Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. Hepatology 2003; 38:999-1007. (Pubitemid 37221683)
5. Boles RG, Martin SK, Blitzer MG, Rinaldo P. Biochemical diagnosis of fatty acid oxidation disorders by metabolite analysis of postmortem liver. Hum Pathol 1994; 25:735-741. (Pubitemid 24249229)
6. Hashimoto T, Cook WS, Qi C, Yeldandi AV, Reddy JK, Rao MS. Defect in peroxisome proliferator-activated receptor alpha-inducible fatty acid oxidation determines the severity of hepatic steatosis in response to fasting. J Biol Chem 2000; 275:28918-28928.
7. Fan CY, Pan J, Usuda N, Yeldandi AV, Rao MS, Reddy JK. Steatohepatitis, spontaneous peroxisome proliferation and liver tumors in mice lacking peroxisomal fatty acyl-CoA oxidase: implications for peroxisome proliferator-activated receptor alpha natural ligand metabolism. J Biol Chem 1998; 273:15639-15645. (Pubitemid 28298179)
8. Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 120:1183-1192. (Pubitemid 32246672)
9. Chalasani N, Gorski JC, Asghar MS, Asghar A, Foresman B, Hall SD, et al. Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis. Hepatology 2003; 37:544-550. (Pubitemid 36258775)
10. Bugianesi E, Gastaldelli A, Vanni E, Gambino R, Cassader M, Baldi S, et al. Insulin resistance in non-diabetic patients withnon-alcoholic fatty liver disease: sites and mechanisms. Diabetologia 2005; 48:634-642. (Pubitemid 40591217)
11. Dasarathy S, Kasumov T, Edmison JM, Gruca LL, Bennett C, Duenas C, et al. Glycine and urea kinetics in non-alcoholic steatohepatitis in human: effect of intralipid infusion. Am J Physiol Gastrointest Liver Physiol 2009; 297:G567-G575.
12. Kalhan SC, Guo L, Edmison J, Dasarathy S, McCullough AJ, Hanson RW, et al. Plasma metabolomic profile in nonalcoholic fatty liver disease. Metabolism 2010; 60:404-413.
13. Pineda TI, Claudel T, Duval C, Kosykh V, Fruchart JC, Staels B. Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor. Mol Endocrinol 2003; 17:259-272. (Pubitemid 36183149)
14. Louet JF, Le MC, Pegorier JP, Decaux JF, Girard J. Regulation of liver carnitine palmitoyltransferase I gene expression by hormones and fatty acids. Biochem Soc Trans 2001; 29:310-316. (Pubitemid 32587523)
15. Oishi K, Uchida D, Ishida N. Circadian expression of FGF21 is induced by PPARalpha activation in the mouse liver. FEBS Lett 2008; 582:3639-3642.
16. Cuevas-Ramos D, Almeda-Valdes P, Aguilar-Salinas CA, Cuevas-Ramos G, Cuevas-Sosa AA, Gomez-Perez FJ. The role of fibroblast growth factor 21 (FGF21) on energy balance, glucose and lipid metabolism. Curr Diabetes Rev 2009; 5:216-220.
17. Inagaki T, Dutchak P, Zhao G, Ding X, Gautron L, Parameswara V, et al. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab 2007; 5:415-425. (Pubitemid 46825496)
18. Zhang X, Yeung DC, Karpisek M, Stejskal D, Zhou ZG, Liu F, et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 2008; 57:1246-1253.
19. Dushay J, Chui PC, Gopalakrishnan GS, Varela-Rey M, Crawley M, Fisher FM, et al. Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology 2010; 139:456-463.
20. Yilmaz Y, Eren F, Yonal O, Kurt R, Aktas B, Celikel CA, et al. Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease. Eur J Clin Invest 2010; 40:887-892.
21. Li H, Bao Y, Xu A, Pan X, Lu J,Wu H, et al. Serum fibroblast growth factor 21 is associated with adverse lipid profiles and gamma- glutamyltransferase but not insulin sensitivity in Chinese subjects. J Clin Endocrinol Metab 2009; 94:2151-2156.
22. Gormsen LC, Gjedsted J, Gjedde S, Norrelund H, Christiansen JS, Schmitz O, et al. Dose-response effects of free fatty acids on amino acid metabolism and ureagenesis. Acta Physiol (Oxf) 2008; 192:369-379. (Pubitemid 351210620)
23. Boden G, Chen X, Rosner J, Barton M. Effects of a 48-h fat infusion on insulin secretion and glucose utilization. Diabetes 1995; 44:1239-1242.
24. Keller U, Gerber PP, Stauffacher W. Fatty acid-independent inhibition of hepatic ketone body production by insulin in humans. Am J Physiol 1988; 254:E694-E699.
25. Machado MV, Ravasco P, Jesus L, Marques-Vidal P, Oliveira CR, Proenca T, et al. Blood oxidative stress markers in non-alcoholic steatohepatitis and how it correlates with diet. Scand J Gastroenterol 2008; 43:95-102.
26. Haque M, Sanyal AJ. The metabolic abnormalities associated with non-alcoholic fatty liver disease. Best Pract Res Clin Gastroenterol 2002; 16:709-731.
27. Kleiner DE, Brunt EM, Van NM, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41:1313-1321. (Pubitemid 40770284)
28. Wein S, Ukropec J, Gasperikova D, Klimes I, Sebokova E. Concerted action of leptin in regulation of fatty acid oxidation in skeletal muscle and liver. Exp Clin Endocrinol Diabetes 2007; 115:244-251. (Pubitemid 46762252)
29. Garcia-Ruiz C, Colell A, Mari M, Morales A, Fernandez-Checa JC. Direct effect of ceramide on the mitochondrial electron transport chain leads to generation of reactive oxygen species: role of mitochondrial glutathione. J Biol Chem 1997; 272:11369-11377. (Pubitemid 27184141)
30. Wieckowska A, Zein NN, Yerian LM, Lopez AR, McCullough AJ, Feldstein AE. In-vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 2006; 44:27-33. (Pubitemid 44049136)
31. Yilmaz Y. Systematic review: caspase-cleaved fragments of cytokeratin 18, the promises and challenges of a biomarker for chronic liver disease. Aliment Pharmacol Ther 2009; 30:1103-1109.
32. Kramer G, Erdal H, Mertens HJ, Nap M, Mauermann J, Steiner G, et al. Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18. Cancer Res 2004; 64: 1751-1756. (Pubitemid 38428698)
33. Dasarathy S, Dasarathy J, Khiyami A, Joseph R, Lopez R, McCullough AJ. Validity of real time ultrasound in the diagnosis of hepatic steatosis: a prospective study. J Hepatol 2009; 51:1061-1067.
34. Kasumov T, Huang H, Chung YM, Zhang R, McCullough AJ, Kirwan JP. Quantification of ceramide species in biological samples by liquid chromatography electrospray ionization tandem mass spectrometry. Anal Biochem 2010; 401:154-161.
35. Tagliacozzi D, Mozzi AF, Casetta B, Bertucci P, Bernardini S, Di IC, et al. Quantitative analysis of bile acids in human plasma by liquid chromatography-electrospray tandem mass spectrometry: a simple and rapid one-step method. Clin Chem Lab Med 2003; 41: 1633-1641. (Pubitemid 38055014)
36. Foster DW, McGarry JD. The regulation of ketogenesis. Ciba Found Symp 1982; 87:120-131.
37. McGarry JD, Foster DW. Regulation of hepatic fatty acid oxidation and ketone body production. Annu Rev Biochem 1980; 49:395-420.
38. Iozzo P, Bucci M, Roivainen A, Nagren K, Jarvisalo MJ, Kiss J, et al. Fatty acid metabolism in the liver, measured by positron emission tomography, is increased in obese individuals. Gastroenterology 2010; 139:846-856.
39. Louet JF, Chatelain F, Decaux JF, Park EA, Kohl C, Pineau T, et al. Long-chain fatty acids regulate liver carnitine palmitoyltransferase I gene (L-CPT I) expression through a peroxisome-proliferator-activated receptor alpha (PPARalpha)-independent pathway. Biochem J 2001; 354:189-197. (Pubitemid 32183459)
40. Reitman ML. FGF21: a missing link in the biology of fasting. Cell Metab 2007; 5:405-407. (Pubitemid 46825502)
41. Potthoff MJ, Inagaki T, Satapati S, Ding X, He T, Goetz R, et al. FGF21 induces PGC-1alpha and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response. Proc Natl Acad Sci U S A 2009; 106:10853-10858.
42. Badman MK, Pissios P, Kennedy AR, Koukos G, Flier JS, Maratos-Flier E. Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab 2007; 5:426-437. (Pubitemid 46825495)
43. Badman MK, Koester A, Flier JS, Kharitonenkov A, Maratos-Flier E. Fibroblast growth factor 21-deficient mice demonstrate impaired adaptation to ketosis. Endocrinology 2009; 150:4931-4940.
44. Fisher FM, Chui PC, Antonellis PJ, Bina HA, Kharitonenkov A, Flier JS, et al. Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes 2010; 59:2781-2789.
45. Huang W, Dedousis N, Bandi A, Lopaschuk GD, O'Doherty RM. Liver triglyceride secretion and lipid oxidative metabolism are rapidly altered by leptin in vivo. Endocrinology 2006; 147:1480-1487. (Pubitemid 43244383)
46. Stingl H, Raffesberg W, Nowotny P, Waldhausl W, Roden M. Reduction of plasma leptin concentrations by arginine but not lipid infusion in humans. Obes Res 2002; 10:1111-1119. (Pubitemid 135686652)
47. Peino R, Fernandez AJ, Penalva A, Considine RV, Rodriguez-Segade S, Rodriguez-Garcia J, et al. Acute changes in free-fatty acids (FFA) do not alter serum leptin levels. J Endocrinol Invest 1998; 21:526-530. (Pubitemid 28461697)
48. Scholz R, Schwabe U, Soboll S. Influence of fatty acids on energy metabolism. 1. Stimulation of oxygen consumption, ketogenesis and CO2 production following addition of octanoate and oleate in perfused rat liver. Eur J Biochem 1984; 141:223-230. (Pubitemid 14106271)
49. Soboll S, Grundel S, Schwabe U, Scholz R. Influence of fatty acids on energy metabolism. 2. Kinetics of changes in metabolic rates and changes in subcellular adenine nucleotide contents and pH gradients following addition of octanoate and oleate in perfused rat liver. Eur J Biochem 1984; 141:231-236. (Pubitemid 14106272)
50. Chocian G, Chabowski A, Zendzian-Piotrowska M, Harasim E, Lukaszuk B, Gorski J. High fat diet induces ceramide and sphingomyelin formation in rat's liver nuclei. Mol Cell Biochem 2010; 340:125-131.
51. Ichi I, Nakahara K, Kiso K, Kojo S. Effect of dietary cholesterol and high fat on ceramide concentration in rat tissues. Nutrition 2007; 23:570-574. (Pubitemid 47002227)
52. Kotronen A, Seppanen-Laakso T, Westerbacka J, Kiviluoto T, Arola J, Ruskeepaa AL, et al. Hepatic stearoyl-CoA desaturase (SCD)-1 activity and diacylglycerol but not ceramide concentrations are increased in the nonalcoholic human fatty liver. Diabetes 2009; 58:203-208.
53. Linder S, Havelka AM, Ueno T, Shoshan MC. Determining tumor apoptosis and necrosis in patient serum using cytokeratin 18 as a biomarker. Cancer Lett 2004; 214:1-9. (Pubitemid 39141193)
54. Wang K, Brems JJ, Gamelli RL, Ding J. Reversibility of caspase activation and its role during glycochenodeoxycholate-induced hepatocyte apoptosis. J Biol Chem 2005; 280:23490-23495. (Pubitemid 40884826)
55. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972; 26:239-257.
56. Wyllie AH, Kerr JF, Currie AR. Cell death: the significance of apoptosis. Int Rev Cytol 1980; 68:251-306. (Pubitemid 11219226)
57. Luo JC, Hwang SJ, Lai CR, Lu CL, Li CP, Tsay SH, et al. Relationships between serum aminotransferase levels, liver histologies and virological status in patients with chronic hepatitis C in Taiwan. J Gastroenterol Hepatol 1998; 13:685-690.